ATAMYO THERAPEUTICS
3:30 PM - 3:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD).
ATA-100, a one-time 1st-in-class gene therapy for LGMD2I/R9 is in phase 1b clinical trial in Europe.
ATA-200, a one-time 1st-in-class gene therapy for LGMD 2C/R5, is in IND phase.
ATA-300, Atamyo’s one-time gene replacement therapy targeting LGMD 2A/R1, is in IND-enabling studies.
Atamyo develops breakthrough capsids, promoters and organ-sparing technologies for AAV-based Gene Therapy.
A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD).
ATA-100, a one-time 1st-in-class gene therapy for LGMD2I/R9 is in phase 1b clinical trial in Europe.
ATA-200, a one-time 1st-in-class gene therapy for LGMD 2C/R5, is in IND phase.
ATA-300, Atamyo’s one-time gene replacement therapy targeting LGMD 2A/R1, is in IND-enabling studies.
Atamyo develops breakthrough capsids, promoters and organ-sparing technologies for AAV-based Gene Therapy.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Ile de France
Company HQ Country:
France
Year Founded:
2020
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
ATA-100, a one-time gene replacement for the treatment of LGMD-R9
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
